Beta
249407

Novel Therapeutic Approaches of Sildenafil Against Rhabdomyolysis-Associated Acute Kidney Injury

Article

Last updated: 03 Jan 2025

Subjects

-

Tags

Section D: Clinical Pharmacy & Pharmacology

Abstract

Objectives: Rhabdomyolysis-associated acute kidney injury (AKI) is a manifestation frequently observed in many cases. Sildenafil (Sild) is a phosphodiesterase-5 inhibitor selected in this study for its experimental protective effects in muscle and kidney injury experimental models. The current study aimed to hypothesize that Sild had a renoprotective effect through the anti-oxidant, anti-inflammatory, and anti-apoptotic mechanisms in glycerol (Gly)-induced rhabdomyolysis rat model. Methods: Male Sprague Dawley rats were allocated into four groups: control group (saline, i.p); Sild control group (5 mg/kg, orally); glycerol (Gly) group (50%, 10 ml/kg, i.m.); prophylactic Sild plus glycerol group (5 mg/kg, orally, 1 hr before glycerol). All treatments were applied as a single dose. Blood samples and renal tissues were collected 24 hr following glycerol injection. Results: Gly produced renal morphological changes, muscle, and renal dysfunction, in addition to increased mortality rates, oxidative stress, renal inflammatory responses, and renal apoptosis. Sild reduced muscle/kidney function disturbances (serum total CK, CK-MB, creatinine, BUN, in addition to urinary creatinine levels), reduced oxidative stress in renal tissue, increased antioxidant defense (TAC, SOD, NRF-2/HO-1), decreased mortality rates, and accelerated renal histological recovery. Additionally, inflammatory mediator levels of TNF-α, NF-κB, and COX-2 were suppressed. Moreover, the study revealed new insights into protection from rhabdomyolysis-associated AKI, through reduction of renal apoptosis by decreasing levels of BAX and increasing levels of BCL-2. Conclusions: Sild protected against rhabdomyolysis-linked renal morphological damage, renal and muscle function disturbances, by decreasing renal oxidative stress, inflammation, and apoptosis. Therefore, Sild proved its muscle/reno-protective impacts, and possibly can be used as a new therapeutic approach for acute muscle and kidney injuries, which represents a new benefit for a common and widely used medication.

DOI

10.21608/aprh.2022.136558.1174

Keywords

sildenafil, rhabdomyolysis, Bcl-2, Bax, Nrf-2/HO-1

Authors

First Name

Ghada

Last Name

El-Tanbouly

MiddleName

Samy

Affiliation

Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt

Email

ghada_samy83@yahoo.com

City

Gamasa

Orcid

0000-0002-0281-1646

First Name

Rania

Last Name

Khalil

MiddleName

-

Affiliation

Department of Pharmacology, Faculty of Pharmacy, Delta University for Science and Technology, Gamasa 11152, Egypt

Email

rania742002@yahoo.com

City

Gamasa

Orcid

-

Volume

6

Article Issue

3

Related Issue

35929

Issue Date

2022-07-01

Receive Date

2022-05-01

Publish Date

2022-07-01

Page Start

144

Page End

154

Print ISSN

2357-0547

Online ISSN

2357-0539

Link

https://aprh.journals.ekb.eg/article_249407.html

Detail API

https://aprh.journals.ekb.eg/service?article_code=249407

Order

5

Type

Research Article

Type Code

318

Publication Type

Journal

Publication Title

Journal of Advanced Pharmacy Research

Publication Link

https://aprh.journals.ekb.eg/

MainTitle

Novel Therapeutic Approaches of Sildenafil Against Rhabdomyolysis-Associated Acute Kidney Injury

Details

Type

Article

Created At

22 Jan 2023